- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05225558
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
A Multicenter, Double-blinded, Randomized, Parallel Design, Phase IIa Clinical Trial to Evaluate the Efficacy, Safety and PK of LCB01-0371 With Vancomycin Versus Vancomycin Monotherapy in Patients With MRSA Bacteremia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The mortality from S aureus bacteremia is higher for MRSA than for methicillin-susceptible S aureus (MSSA), typically at 20% to 25%.
The current standard therapy for MRSA bacteremia is vancomycin. Vancomycin has many shortcomings, including poor tissue penetration and slow killing time. Vancomycin has reduced efficacy against MRSA and tended to increase the MIC level (called MIC creep). Addition of Delpazolid to Vancomycin could improve the known drawbacks of Vancomycin alone.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: YunHee Lee
- Phone Number: +82 2 461 0716
- Email: yhlee@legochembio.com
Study Locations
-
-
-
Ansan, Korea, Republic of
- Not yet recruiting
- Korea University Ansan Hospital
-
Contact:
- Yunhee Lee
-
Gwangju, Korea, Republic of
- Recruiting
- Chonnam National University Hospital
-
Contact:
- Yunhee Lee
-
Gwangju, Korea, Republic of
- Not yet recruiting
- Chosun University Hospital
-
Contact:
- Yunhee Lee
-
Seoul, Korea, Republic of
- Recruiting
- Asan Medical Center
-
Contact:
- Yunhee Lee
-
Seoul, Korea, Republic of
- Not yet recruiting
- Severance Hospital
-
Contact:
- Yunhee Lee
-
Seoul, Korea, Republic of
- Recruiting
- Seoul National University Bundang Hospital
-
Contact:
- Yunhee Lee
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female ≥19 years of age on the date of written consent
- Subject who has confirmed positive MRSA at least one set of blood cultures within 72 hours prior to randomization OR, Subject who has confirmed positive MRSA at least one set of blood culture whthin 96 hours prior to randomization and treated with vancomycin at least 72 hours prior to randomization
- Subject who has clinical symptoms or signs of MRSA bacteremia according to the judgment of the investigator
- Subject who voluntarily decides to participate in this clinical trial after being explained fully, and agrees in writing to implement the clinical trial compliance matters
Exclusion Criteria:
- Subject with polymicrobial bacteremia or infections including Gram-negative strain
- Subject undergoing or in need of treatment with antiviral or antifungal drugs
- Subject who has received treatment for MRSA bacteremia within 3 months of screening (Subjects who have "re-infection" by investigator's judgement may participant in the study.)
- Subject who has been administered effective antibiotics against MRSA (Vancomycin, etc.) for more than 96 hours prior to the first investigational product administration. (However, antibiotics effective for MRSA such as vancomycin are allowed to be administered for less than 72 hours.)
- Septic shock patients
- Subject who has hypersensitivity to vancomycin or linezolid
- Subject who has a history of hypersensitivity to peptide-based antibiotics and aminoglycoside-based antibiotics
- Subject who is receiving a MAO inhibitor(MAOI) or has received MAOI within 14 days of the first investigational drug administration
- Subject taking serotonin reuptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptan), meperidine, or buspirone
- Subject with severely decreased immunity (Severe neutropenia (ANC <0.5×10^9/L) etc.)
- Subject who is expected to die within 2 days due to serious complications of MRSA bacteremia based on the judgment of the investigator
- Body Mass Index (BMI) ≥35 kg/m2
- Subject who is unable to administer drugs orally
- Pregnant or lactating female, female or male with childbearing potential who disagrees with the use of appropriate contraceptive methods during the study and up to 14 days after the last dose of the investigator product
- Subject who has received other clinical trial drugs within 30 days of screening
- Subject who is not suitable for participation in this clinical trial according to the medical findings of investigators
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination therapy - Vancomycin IV plus Delpazolid 800 mg, PO, BID
Intravenous vancomycin dosed as per 2020 IDSA guideline Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion are recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L. Depending on the investigator's judgment, it is allowed to change to daptomycin after at least one week of administration of vancomycin, and also it is allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of vancomycin (including daptomycin). |
BID, PO
Other Names:
IV infusion per 2020 IDSA guideline
|
Placebo Comparator: Monotherapy - Vancomycin IV plus Placebo of Delpazolid
Intravenous vancomycin dosed as per 2020 IDSA guideline Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion are recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L. Depending on the investigator's judgment, it is allowed to change to daptomycin after at least one week of administration of vancomycin, and also it is allowed to change to oral antibiotics other than oxazolidinones after two weeks of administration of vancomycin (including daptomycin). |
IV infusion per 2020 IDSA guideline
BID, PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall cure rate by Day 14 (composite response rate: clinical improvement plus clearance of bacteremia)
Time Frame: by Day 14
|
'Overall cure' means that there are no symptoms of infection that existed when enrolled in the clinical trial, there are no new metastatic infection due to MRSA and no new infection (clinical improvement), and MRSA negative is confirmed twice in a row as a result of blood culture tests ( clearance of bacteremia). a. If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as 'clearance of bacteremia'. |
by Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall cure rate by End of Treatment (EOT)
Time Frame: by EOT visit (up to 6 weeks)
|
composite response rate: clinical improvement plus clearance of bacteremia
|
by EOT visit (up to 6 weeks)
|
Mortality due to MRSA bacteremia
Time Frame: by Test of Cure (TOC) (=4 weeks after EOT (up to 6 weeks))
|
Proportion of subjects who died due to MRSA bacteremia
|
by Test of Cure (TOC) (=4 weeks after EOT (up to 6 weeks))
|
Microbiological relapse rate
Time Frame: by TOC (=4 weeks after EOT)
|
Defined as a positive blood culture to MRSA when previous ones were negative
|
by TOC (=4 weeks after EOT)
|
Clearance of MRSA bacteremia rate
Time Frame: Day 3, Day 5, Day 7, Day 14, EOT (up to 6 weeks)
|
Proportion of subjects who confirmed MRSA negative two consecutive set in the blood culture test
|
Day 3, Day 5, Day 7, Day 14, EOT (up to 6 weeks)
|
Persistent MRSA bacteremia rate
Time Frame: Day 3, Day 5, Day 7, Day 14
|
Proportion of subjects who have positive results on blood culture tests
|
Day 3, Day 5, Day 7, Day 14
|
Time to clearance of MRSA bacteremia
Time Frame: by EOT (up to 6 weeks)
|
If negative in the blood culture test is confirmed for the first time, additional test will be performed the next day, and if it results negative for a total of two times in a row, it is judged as clearance of bacteremia.
The period until the clearance of bacteremia is defined as the period (day) from the date of the first blood culture test within 72 hours prior to randomization with MRSA positive (index blood culture) to the date of the blood culture test with the first negative result confirmed.
|
by EOT (up to 6 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vancomycin minimum inhibitory concentration (MIC) levels
Time Frame: up to 6 weeks
|
Vancomycin MIC level
|
up to 6 weeks
|
Delpazolid MIC levels
Time Frame: up to 6 weeks
|
Delpazolid MIC level by BMD
|
up to 6 weeks
|
Pharmacokinetics (PK) parameters: Cmax
Time Frame: up to 6 weeks
|
Peak Plasma Concentration (Cmax)
|
up to 6 weeks
|
Pharmacokinetics (PK) parameters: AUC(0-last)
Time Frame: up to 6 weeks
|
the area under the concentration-time curve from dosing (time 0) to the time of the last measured concentration
|
up to 6 weeks
|
Pharmacokinetics (PK) parameters: Half-life
Time Frame: up to 6 weeks
|
Half-life
|
up to 6 weeks
|
Pharmacokinetics (PK) parameters: Tmax
Time Frame: up to 6 weeks
|
time to reach Cmax
|
up to 6 weeks
|
Pharmacokinetics (PK) parameters: Cl
Time Frame: up to 6 weeks
|
Clearance
|
up to 6 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Bacterial Infections
- Bacterial Infections and Mycoses
- Sepsis
- Bacteremia
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Vancomycin
- Delpazolid
- Oxazolidinones
Other Study ID Numbers
- LCB35-0371-21-2-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MRSA Bacteremia
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterCenters for Disease Control and Prevention; Sage Products, Inc.UnknownMRSA Infection | MRSA Colonization | VRE Infection | VRE Colonization | Nosocomial BacteremiaUnited States
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Vanderbilt University Medical CenterRecruitingBloodstream Infection | Vancomycin | MRSA Bacteremia | Sepsis BacterialUnited States
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterJohns Hopkins University; Washington University School of Medicine; Weill Medical... and other collaboratorsCompletedMRSA Infection | MRSA Colonization | VRE Infection | VRE Colonization | Nosocomial Bacteremia | Nosocomial FungemiaUnited States
-
ContraFectNo longer availableCovid19 | MRSA Bacteremia | MRSA Bloodstream Infection | MRSA Right-sided EndocarditisUnited States
-
Forest LaboratoriesCompletedStaphylococcus Aureus Bacteremia | Methicillin-resistant Staphylococcus Aureus (MRSA) BacteremiaUnited States
-
Hvidovre University HospitalRecruiting
-
Children's Hospital of PhiladelphiaJohns Hopkins University; University of Pennsylvania; Centers for Disease Control... and other collaboratorsRecruitingSepsis | Septic Shock | Sepsis, Severe | Sepsis Bacteremia | Sepsis Mrsa | Antimicrobial - Induced Nephropathy | Septic SyndromeUnited States
-
Indiana UniversityWithdrawnHospital Acquired MRSA | Community Acquired MRSAUnited States
Clinical Trials on Delpazolid
-
LegoChem Biosciences, IncCompletedHealthyKorea, Republic of
-
LigaChem Biosciences, Inc.Active, not recruitingMycobacterium Abscessus Infection | Nontuberculous Mycobacterium InfectionKorea, Republic of
-
LegoChem Biosciences, IncCompleted
-
LegoChem Biosciences, IncTerminatedHealthyKorea, Republic of
-
LegoChem Biosciences, IncCompletedHealthyKorea, Republic of
-
LegoChem Biosciences, IncCompleted
-
LegoChem Biosciences, IncCompleted
-
LegoChem Biosciences, IncCompleted
-
LegoChem Biosciences, IncCompletedHealthyKorea, Republic of
-
LegoChem Biosciences, IncRadboud University Medical Center; University of California, San Francisco; Ludwig-Maximilians...CompletedPulmonary Tuberculosis | Infections and InfestationsTanzania, South Africa